ResearcherTUM KlinikumActive in the last 2 years

Henrik Einwächter

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8823-5116; OpenAlex author ID A5008927439. Sources: OpenAlex.

Their work

Papers: 4 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 20

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 4

Correction: Mitochondrial superoxide dismutase controls metabolic plasticity in pancreatic cancer. Last author DOI 10.1186/s12964-026-02750-1 ↗
A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development. Co-author DOI 10.1038/s41467-025-56493-7 ↗
Mitochondrial superoxide dismutase controls metabolic plasticity in pancreatic cancer. Last author DOI 10.1186/s12964-025-02555-8 ↗
Loss of Wasl improves pancreatic cancer outcome. Co-author DOI 10.1172/jci.insight.127275 ↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Roland Michael Schmid · 4 shared papers, 2020–2026 · strength 0.91
- Paper Correction: Mitochondrial superoxide dismutase controls metabolic plasticity in pancreatic cancer. DOI 10.1186/s12964-026-02750-1 ↗
- Paper Mitochondrial superoxide dismutase controls metabolic plasticity in pancreatic cancer. DOI 10.1186/s12964-025-02555-8 ↗
- Paper A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic canc… DOI 10.1038/s41467-025-56493-7 ↗
Sankaranarayanan Ramasubramanian · 2 shared papers, 2025–2026 · strength 0.66
- Paper Correction: Mitochondrial superoxide dismutase controls metabolic plasticity in pancreatic cancer. DOI 10.1186/s12964-026-02750-1 ↗
- Paper Mitochondrial superoxide dismutase controls metabolic plasticity in pancreatic cancer. DOI 10.1186/s12964-025-02555-8 ↗
Marina Lesina · 2 shared papers, 2020–2025 · strength 0.25
- Paper A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic canc… DOI 10.1038/s41467-025-56493-7 ↗
- Paper Loss of Wasl improves pancreatic cancer outcome. DOI 10.1172/jci.insight.127275 ↗
Maximilian Reichert · 2 shared papers, 2020–2025 · strength 0.25
- Paper A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic canc… DOI 10.1038/s41467-025-56493-7 ↗
- Paper Loss of Wasl improves pancreatic cancer outcome. DOI 10.1172/jci.insight.127275 ↗
Roland Rad · 2 shared papers, 2020–2025 · strength 0.25
- Paper A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic canc… DOI 10.1038/s41467-025-56493-7 ↗
- Paper Loss of Wasl improves pancreatic cancer outcome. DOI 10.1172/jci.insight.127275 ↗
Anne T. Schneider · 1 shared paper, 2025 · strength 0.16
- Paper A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic canc… DOI 10.1038/s41467-025-56493-7 ↗
Aristeidis Papargyriou · 1 shared paper, 2025 · strength 0.16
- Paper A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic canc… DOI 10.1038/s41467-025-56493-7 ↗
Thilo Hackert · 1 shared paper, 2025 · strength 0.16
- Paper A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic canc… DOI 10.1038/s41467-025-56493-7 ↗
Matthias M. Gaida · 1 shared paper, 2025 · strength 0.16
- Paper A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic canc… DOI 10.1038/s41467-025-56493-7 ↗
Wolfram Trudo Knoefel · 1 shared paper, 2025 · strength 0.16
- Paper A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic canc… DOI 10.1038/s41467-025-56493-7 ↗
Sebastian Mueller · 1 shared paper, 2025 · strength 0.16
- Paper A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic canc… DOI 10.1038/s41467-025-56493-7 ↗
Valentina Leone · 1 shared paper, 2025 · strength 0.16
- Paper A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic canc… DOI 10.1038/s41467-025-56493-7 ↗
Iréne Esposito · 1 shared paper, 2025 · strength 0.16
- Paper A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic canc… DOI 10.1038/s41467-025-56493-7 ↗
Tom Luedde · 1 shared paper, 2025 · strength 0.16
- Paper A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic canc… DOI 10.1038/s41467-025-56493-7 ↗
Hana Algül · 1 shared paper, 2025 · strength 0.16
- Paper A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic canc… DOI 10.1038/s41467-025-56493-7 ↗
Ana Hidalgo‐Sastre · 1 shared paper, 2020 · strength 0.09
- Paper Loss of Wasl improves pancreatic cancer outcome. DOI 10.1172/jci.insight.127275 ↗
Zahra Dantes · 1 shared paper, 2020 · strength 0.09
- Paper Loss of Wasl improves pancreatic cancer outcome. DOI 10.1172/jci.insight.127275 ↗
Jens Thomas Siveke · 1 shared paper, 2020 · strength 0.09
- Paper Loss of Wasl improves pancreatic cancer outcome. DOI 10.1172/jci.insight.127275 ↗
Guido von Figura · 1 shared paper, 2020 · strength 0.09
- Paper Loss of Wasl improves pancreatic cancer outcome. DOI 10.1172/jci.insight.127275 ↗
Clara Lubeseder–Martellato · 1 shared paper, 2020 · strength 0.09
- Paper Loss of Wasl improves pancreatic cancer outcome. DOI 10.1172/jci.insight.127275 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.